Filing Flows › Stoke Therapeutics (STOK) › Q2 2026
Stoke Therapeutics (STOK) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 3, 2026
Stoke Therapeutics (STOK) reported revenue of $9.3M for the second quarter 2026 (Q2 2026), -33% from a year earlier and +50% from the quarter before. Operating margin was -701.7%, net loss $61.6M (660.8% of revenue).
Stoke Therapeutics, Q2 2026: revenue $9.3M (-32% year over year), operating margin -701.7%, net loss $61.6M, operating cash flow −$56.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.3M | +50% | -33% |
| Operating profit | −$65.4M | — | — |
| Net earnings | −$61.6M | — | — |
| Operating cash flow | −$56.6M | — | — |
What changed
Revenue was $9.3M in Q2 2026, down 33% year over year and up 50% from the previous quarter.
Operating costs exceeded revenue by $65.4M, an operating margin of -701.7%. Total costs grew 82% against a revenue fall of 33%. The fastest-growing cost line was Research & development (+91%). The quarter ended with a net loss of $61.6M, wider than the previous quarter's $50.0M loss.
Operating cash flow was −$56.6M. Non-cash charges added back $458K of depreciation and $10.8M of share-based compensation. Working capital and other items used $6.2M. Capital expenditures of $2.0M exceeded it, leaving free cash flow of −$58.6M.
Questions
What was Stoke Therapeutics' revenue in the second quarter 2026?
Stoke Therapeutics (STOK) reported revenue of $9.3M for the second quarter 2026 (Q2 2026), -33% from a year earlier and +50% from the quarter before.
Was Stoke Therapeutics profitable in the second quarter 2026?
Operating loss was $65.4M (-701.7% of revenue) and net loss $61.6M.
Source: Stoke Therapeutics 10-Q on SEC EDGAR.